Dynavax Technologies Co. (NASDAQ:DVAX) Short Interest Update

Dynavax Technologies Co. (NASDAQ:DVAX) was the recipient of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 17,040,000 shares, a decrease of 5.6% from the September 15th total of 18,050,000 shares. Based on an average trading volume of 2,000,000 shares, the days-to-cover ratio is currently 8.5 days.

Analyst Ratings Changes

A number of brokerages have recently commented on DVAX. The Goldman Sachs Group cut their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $23.67.

Dynavax Technologies Stock Down 1.0 %

Shares of NASDAQ DVAX opened at $10.92 on Friday. The company’s 50 day moving average price is $11.06 and its 200-day moving average price is $11.28. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $15.15. The company has a market capitalization of $1.43 billion, a P/E ratio of 182.00 and a beta of 1.37.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The firm had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. During the same period last year, the company posted $0.03 EPS. Equities analysts forecast that Dynavax Technologies will post 0.16 earnings per share for the current year.

Institutional Investors Weigh In On Dynavax Technologies

A number of large investors have recently bought and sold shares of DVAX. GAMMA Investing LLC grew its stake in shares of Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,685 shares during the period. Algert Global LLC acquired a new stake in Dynavax Technologies in the second quarter valued at approximately $140,000. Sanctuary Advisors LLC acquired a new stake in Dynavax Technologies in the second quarter valued at approximately $182,000. XTX Topco Ltd bought a new stake in shares of Dynavax Technologies during the second quarter valued at approximately $184,000. Finally, Duality Advisers LP acquired a new position in shares of Dynavax Technologies during the first quarter worth approximately $227,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.